Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study

摘要

Background and aim Information describing the efficacy and safety of infliximab (IFX) for Crohn's disease (CD) in China is limited. The aim of this study was to report response rates, relapse rates after IFX-induced remission, and adverse events, and identify factors associated with relapse in a cohort of CD patients treated with IFX in a Chinese center.